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The Vif Protein of HIV Triggers Degradation of the
Human Antiretroviral DNA Deaminase APOBEC3G
had been cotransfected with Vif (Figure 1A). A similar
destabilizing effect was not observed when vif was co-
transfected with a nonchimaeric GFP target (Figure 1B).
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Medical Research Council
Laboratory of Molecular Biology Cotransfecting target cells with a plasmid encoding a
red fluorescent protein (RFP) together with plasmidsHills Road, Cambridge CB2 2QH
United Kingdom encoding GFP-APOBEC3G and Vif (orVif) revealed that
the red and green fluorescence diminished with similar
kinetics when using the nonfunctional Vif; the fluores-
cence of most cells was therefore distributed along the
Summary diagonal in the 2D fluorescence plots (Figure 1C). How-
ever, when coexpressing Vif itself, a greatly accelerated
APOBEC3G is a human cellular enzyme that is incorpo- disappearance of the green (GFP-APOBEC3G) but not
rated into retroviral particles and acts to restrict ret- the red (control RFP) fluorescence was observed.
roviral replication in infected cells by deaminating dC Pulse-chase experiments showed that coexpression of
to dU in the first (minus)-strand cDNA replication in- Vif causes accelerated degradation of GFP-APOBEC3G
termediate [1–5]. HIV, however, encodes a protein (vi- but not of a nonchimaeric GFP internal control (Figure
rion infectivity factor, Vif [6, 7]), which overcomes 2A). While both the fluorescence (Figure 1) and biosyn-
APOBEC3G-mediated restriction but by an unknown thetic labeling experiments (Figure 2A) reveal that Vif
mechanism. Here, we show that Vif triggers APOBEC3G accelerates GFP-APOBEC3G turnover, there is an ap-
degradation by a proteasome-dependent pathway and parent difference in the kinetics observed in the two
that an 80 amino acid region of APOBEC3G sur- assays. This presumably reflects the fact that whereas
rounding its first zinc coordination motif is sufficient the pulse-chase experiments monitor the disappearance
to confer the ability to partake in an interaction involv- over a shortish time (up to 8 hr) of a bolus of radiolabeled
ing Vif. Inhibitors of this interaction might therefore GFP-APOBEC3G that was synthesized in a short pulse,
prove therapeutically useful in blocking Vif-mediated the fluorescence assay monitors the dynamic change
APOBEC3G destruction. in total GFP-APOBEC3G as analyzed over a long period
(96 hr) during which the Vif:GFP-APOBEC3G ratio will
be continuously increasing.
Results and Discussion Furthermore, while chloroquine (an inhibitor of the
lysosomal pathway) did not suppress the Vif accelera-
While the mechanism by which Vif overcomes APOBEC3G- tion of GFP-APOBEC3G degradation, the Vif enhance-
mediated restriction of viral infection is unknown, it is ment of GFP-APOBEC3G turnover was largely blocked
evident that Vif (like APOBEC3G) needs to be expressed by ALLN (a calpain I/proteasome inhibitor) as well as by
in the viral-producer cell (rather than just in the infected lactacystin, MG132, and proteasome inhibitor I (more
cell target) in order to exhibit an effect on viral replication specific proteasome inhibitors) (Figure 2A).
[8–11]. One could imagine that Vif might mediate its Thus, it would seem likely that Vif stimulates APOBEC3G
effect by inhibiting the catalytic activity of APOBEC3G, degradation by a ubiquitin-dependent pathway. Indeed,
by blocking APOBEC3G incorporation into virions, by Western blot analysis of GFP-APOBEC3G that has been
triggering APOBEC3G degradation, or by protecting viral immunoprecipitated from cells in which it has been
replication intermediates from access by APOBEC3G. coexpressed with an HA-tagged ubiquitin together with
Therefore, to discriminate between some of these possi- Vif or Vif reveals a somewhat smeary ladder character-
bilities, we started by asking whether Vif might have an istic of multi/polyubiquitination [12]. The intensity of this
effect on APOBEC3G in the absence of the viral genome ladder is enhanced in the presence of Vif (Figure 2B).
and its products. Vif has been reported to interact with APOBEC3G [5].
A plasmid was constructed that directs the expression We were therefore interested to ascertain whether this
of a fusion protein of APOBEC3G with GFP (green fluo- interaction correlated with the induction of APOBEC3G
rescent protein). This construct, which is effective in degradation. We first asked which region of APOBEC3G
restricting retroviral infection in the previously described was needed for Vif interaction. The predicted amino acid
MLV-based assay ([2]; data not shown), was transfected sequence of APOBEC3G reveals the presence of two
into 293T cells together with a plasmid encoding either likely zinc-coordination motifs which, given that the re-
a functional or mutated version of HIV Vif. The GFP- lated deaminases APOBEC1 and AID contain a single
APOBEC3G gene was well expressed but the stability such motif, suggests that the APOBEC3G polypeptide
of the fluorescence was greatly diminished in cells that might possess two deaminase active sites [13]. Immuno-
precipitation experiments performed using extracts of 293T
cells that had been cotransfected with a Vif-expressing
*Correspondence: silvoc@mrc-lmb.cam.ac.uk (S.G.C.), msn@mrc- plasmid together with vectors directing the expression
lmb.cam.ac.uk (M.S.N.)
of different GFP-APOBEC3G chimaeras indeed provided1Present address: Department of Biochemistry, Molecular Biology
evidence of an interaction between Vif and APOBEC3G;and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321
Church Street Southeast, Minneapolis, Minnesota 55455. the results indicated that the amino-terminal (but not
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Figure 1. HIV Vif Accelerates Degradation of
APOBEC3G Fusion Proteins
(A) Flow cytometric analysis of GFP fluores-
cence in 293T cells that have been cotrans-
fected with plasmids directing the expression
of GFP-APOBEC3G (AB3G) and either a func-
tional or mutated Vif (Vif or Vif, respectively)
shown at various times after transfection.
Green fluorescence is indicated on the x axis.
The fluorescence in FL2 (y axis) is due to very
bright green fluorescent cells, whose fluores-
cence leaks into FL2.
(B) Quantitation of GFP fluorescence as a
function of time, taking fluorescence at 36 hr
as 100%. The results are shown for experi-
ments in which GFP-APOBEC3G (AB3G) fu-
sion protein or GFP alone (GFP) were ex-
pressed in the presence of functional or
mutated versions of HIV Vif. The results are
the average standard deviation of between
five and nine independent experiments.
(C) Flow cytometric analysis of both GFP (x
axis) and RFP (y axis) fluorescence in 293T
cells that have been cotransfected with plas-
mids directing the expression of GFP-
APOBEC3G (AB3G), red fluorescent protein
(RFP), and either a functional or mutated Vif
shown at various times after transfection.
the carboxy-terminal) portion of APOBEC3G was suffi- alternatively, they are intrinsically unstable with or with-
out Vif (data not shown).cient to mediate this interaction (Figures 3A and 3B).
While APOBEC3G can act directly on single-stranded While our results concerning a physical interaction
involving Vif and APOBEC3G agree with and extendDNA [2] and Vif has been shown to be able to bind
nucleic acids [14–16], it is notable that the Vif/APOBEC3G upon those of Mariani et al. [5], our findings that Vif
triggers APOBEC3G degradation results differ frominteraction is not abolished by treating the extracts with
RNase and DNase, although we still cannot conclude those of these authors who, while noting diminished
abundance of APOBEC3G in Vif-expressing cells as wellthat the interaction is necessarily direct. Analysis of fur-
ther chimaeras revealed that an 80 amino acid sequence as the presence of APOBEC3G degradation products,
did not find that Vif coexpression affected the half-lifeencompassing the first putative zinc-coordination motif
of APOBEC3G is sufficient to confer the ability to partake of APOBEC3G. The explanation for this discrepancy re-
mains a matter for speculation. We do not believe ourin the interaction with Vif (Figures 3A and 3B).
We then asked whether the regions of APOBEC3G results are artifacts peculiar to our fusion proteins: dur-
ing the review of this manuscript, others have describedthat conferred the ability to interact with Vif were also
able to confer Vif-dependent destabilization. Pulse- experiments that use different APOBEC3G expression
constructs but which have led them to similar conclu-chase (Figure 3C) as well as immunofluorescence (data
not shown) experiments revealed that GFP fusions con- sions [19–21]. Rather, we note that the Vif antagonism
of the antiretroviral effect of APOBEC3G appears to betaining the C-terminal (non-Vif-interacting) domain of
APOBEC3G were stable and not subject to Vif-depen- critically sensitive to the Vif:APOBEC3G ratio [1–3, 5,
17, 18]. Indeed, we have found that the effect of Vif ondent degradation. In contrast, GFP fusions with the
N-terminal (Vif-interacting) domain of APOBEC3G were APOBEC3G turnover as monitored in the cotransfection
assay is sensitive to the ratio of Vif to APOBEC3G ex-inherently unstable, not exhibiting any evident additional
destabilization in the presence of Vif. Indeed, so far, we pression as well as to the time course used to monitor
APOBEC3G turnover (data not shown).have not been able to identify GFP-APOBEC3G fusions
comprising subregions of the APOBEC3G N-terminal Thus, Vif (in the absence of other viral components)
is able to trigger degradation of APOBEC3G through adomain that exhibit Vif-dependent degradation. Either
they are intrinsically stable and do not interact with Vif; proteasome-dependent pathway. This correlates with
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Figure 2. APOBEC3Gs Degraded through a
Proteasome-Dependent Pathway
(A) Pulse-chase analysis of GFP-APOBEC3G
degradation in the presence or absence of
Vif. 293T cells expressing GFP-APOBEC3G
(AB3G), GFP (GFP), and either a functional or
mutated HIV Vif (Vif orVif, respectively) were
pulsed for 30 min with [L-35S]Cys-Met and
then chased for the indicated number of
hours in the absence or presence of the spec-
ified inhibitor. A representative gel is shown
together with a graph summarizing the results
(means  standard deviations) of three to six
independent experiments. The graphs show
the amount of labeled protein after various
lengths of chase expressed as a percentage
of the radioactivity at time zero.
(B) Polyubiquitination of GFP-APOBEC3G.
293T cells were cotransfected with GFP-
APOBEC3G, GFP, HA-ubiquitin, and func-
tional or mutated Vif as indicated. The bulk
(90%) of the cell extracts were subjected to
immunoprecipitation with anti-GFP antibod-
ies. These immunoprecipitates (or aliquots
[2%] of total lysates) were then subjected to
SDS/PAGE, and the Western blots were
probed with anti-HA or anti-GFP antibodies.
The migration of bands corresponding to
GFP-APOBEC3G fusion protein (AB3G) and
the GFP internal control for protein loading
(GFP) are indicated; the bands presumed to
correspond to multi/polyubiquitinated GFP-
APOBEC3G are indicated by a bracket. The
intensity of the multi/polyubiquitinated GFP-
APOBEC3G smear (after normalization for to-
tal GFP-APOBEC3G amounts [as determined
in the anti-GFP Western blot] and correction
for the total level of ubiquitination [as moni-
tored in the anti-HA-tag Western blots of total
lysates]) was increased by 1.9 fold (SD 0.39
from five independent experiments) in the
presence of Vif.
GAG), APOBEC3G-N1 (AAActcgagATGAAGCC-TCACTTCAGA;the observation that a region in the vicinity of the first
AAGctgcagTCATTCGGAATACACCTGGCCTC), APOBEC3G-N2 (AAAzinc binding domain of APOBEC3G is sufficient to confer
ctcga-gATGTTTCGAGGCCAGGTGTATT; AAGctgcagTCAGTAGAGthe ability to partake in an interaction involving Vif––
GCGGGCAACGAAGA), APOBEC3G-N3 (AAActcgagATGGCCCGC
information which might prove useful in designing pep- CTCTACTACTTCT; AAGctgcagTCACCAA-CAGTGCTGAAATTC
tide inhibitors. While we do not know the details of the GTC), and APOBEC3G-N4 (AAActcgagATGGAATTTCAGCACTGTT
GGAG; AAGctgcagTCAATCCATCGAGTGTCTGAGAATC). Plasmidsmechanism by which Vif-induced destabilization of
expressing Vif and Vif were as used previously [2], the plasmidAPOBEC3G occurs, the data are consistent with a model
directing the expression of an HA-tagged ubiquitin was kindly pro-in which formation of a complex involving Vif causes a
vided by J. Sale, and the plasmid encoding the red fluorescent
conformational shift in APOBEC3G that favors its degra- protein was pHcRed1-C1 (BD Biosciences).
dation. Fugene 6 (Roche) was used to transfect plasmids into 293T cells
via lipofection, and fluorescence was analyzed via flow cytometry
Experimental Procedures (Becton-Dickinson) at the peak of the expression (36 hr after trans-
Plasmid pEGFP-C3 (BD Biosciences) was used as the expression fection) and every 24 hr thereafter. For biosynthetic labeling, cells
vector for GFP; plasmids directing expression of GFP-APOBEC3G (at 36 hr after transfection) were preincubated in DMEM without
fusion proteins were derived from pEGFP-C3 by inserting PCR- cysteine and methionine (Sigma); 4 mM L-glutamine; 0.1% FCS for
amplified APOBEC3G fragments downstream of the EGFP coding 2 hr prior to a 30 min pulse with medium containing L-[35S]Cys-Met
sequence, between the XhoI and PstI sites. Oligonucleotides used (0.1 mCi/ml) (Redivue Pro-Mix; Amersham) followed by a chase in
for amplifying APOBEC3G (or portions thereof) were APOBEC3G-N complete medium. Where required, chloroquine (100 M; Sigma),
(AAActcgagGCCACCATGAAGCCTCACTTCAGA; AAACTGCAGCGT N-Acetyl-Leu-Leu-Norleu-Al (ALLN; 100 M; Sigma), lactacystin (10
CACCTAGTCAGAGCTCNNNNNN), APOBEC3G-C (AATctcgagATG M), MG-132 (50M), or proteasome inhibitor I (50M; Calbiochem)
were added during the preincubation, incubation, and chase.GATCCACCCACATTCAC; AAGctgcagTCAGTTTTCCTGATTCTG
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Figure 3. The N-Terminal Domain of APO-
BEC3G Confers Instability and the Ability to
Partake in a Vif Interaction
(A) Schematic representation of APOBEC3G
polypeptide. The gray ellipses represent the
positions of the putative zinc-coordination
domains; the locations of corresponding
exon junctions in the mRNA structure are
shown as thin vertical lines. The constructs
that were analyzed are depicted as horizontal
lines above and below the APOBEC3G struc-
ture. AB3G-N (amino acid residues 1–215 of
APOBEC3G), AB3G-C (residues 197–384), N1
(residues 1–61), N2 (residues 54–124), N3
(residues 121–161), and N4 (residues 156–
198).
(B) Interaction of Vif with APOBEC3G and its
subdomains. Extracts from cells that had
been transfected with plasmids encoding Vif
together with plasmids encoding fusion pro-
teins of GFP with subdomains of APOBEC3G
were immunoprecipitated with anti-GFP anti-
bodies and immunoblots were probed with
anti-Vif antibodies. Aliquots (4%) of the total
cell extracts were also loaded and blotted
with anti-GFP or anti-Vif antibodies as con-
trols for expression. Where specified, RNaseA
(0.5 mg/ml) and DNaseI (130 U/ml) treatment
was carried out for 15 min at 37C before the
addition of anti-GFP antibodies.
(C) Pulse-chase analysis of the stability of
GFP fusion proteins containing the first do-
main or second domain of APOBEC3G. 293T
cells coexpressing either GFP-APOBEC3G-N
(AB3G-N) or GFP-APOBEC3G-C (AB3G-C)
together with GFP and either a functional or
mutated HIV Vif (respectively, Vif and Vif)
were pulsed for 30 min with [35S]Cys-Met and
then chased for the indicated lengths of time
(hours). A representative gel is shown to-
gether with a graph summarizing the results
from three independent experiments.
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